Cancer Drug Clinical Trial Endpoints Should Consider Quality-Of-Life PROs, Advocate Says
Executive Summary
Former FDA advisory committee patient representative petitions agency to require comparison of quality of life-related patient reported outcomes for surrogate endpoints, including progression-free survival.